Orchard Therapeutics Analyst Ratings
Orchard Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 557.64% | Oppenheimer | → $34 | Reiterates | Outperform → Outperform |
| 06/27/2023 | 190.14% | Cantor Fitzgerald | → $15 | Reiterates | Overweight → Overweight |
| 06/13/2023 | 557.64% | Oppenheimer | $37 → $34 | Maintains | Outperform |
| 03/28/2023 | 190.14% | Cantor Fitzgerald | $3 → $15 | Maintains | Overweight |
| 05/13/2022 | -22.63% | Barclays | $6 → $4 | Maintains | Overweight |
| 04/01/2022 | — | SMBC Nikko | Downgrades | Outperform → Neutral | |
| 03/31/2022 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 11/16/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 11/05/2021 | 151.45% | Oppenheimer | $15 → $13 | Maintains | Outperform |
| 08/18/2021 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 03/02/2021 | 190.14% | JP Morgan | $14 → $15 | Assumes | → Overweight |
| 01/07/2021 | 209.48% | Cantor Fitzgerald | → $16 | Initiates Coverage On | → Overweight |
| 04/01/2020 | 441.59% | Oppenheimer | $29 → $28 | Maintains | Outperform |
| 09/17/2019 | 499.61% | Guggenheim | → $31 | Initiates Coverage On | → Buy |
| 09/05/2019 | 306.19% | Barclays | → $21 | Initiates Coverage On | → Overweight |
| 08/30/2019 | 402.9% | Oppenheimer | → $26 | Initiates Coverage On | → Outperform |
| 12/17/2018 | 306.19% | Goldman Sachs | $18 → $21 | Upgrades | Neutral → Buy |
| 11/26/2018 | 422.24% | Cowen & Co. | → $27 | Initiates Coverage On | → Outperform |
| 11/26/2018 | 248.16% | Goldman Sachs | → $18 | Initiates Coverage On | → Neutral |
| 11/26/2018 | 383.56% | Wedbush | → $25 | Initiates Coverage On | → Outperform |
| 11/26/2018 | — | JP Morgan | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 08/09/2023 | 557.64% | 奥本海默 | →$34 | 重申 | 跑赢→跑赢大盘 |
| 2023年6月27日 | 190.14% | 康托·菲茨杰拉德 | →$15 | 重申 | 超重→超重 |
| 2023/06/13 | 557.64% | 奥本海默 | $37→$34 | 维护 | 跑赢大盘 |
| 03/28/2023 | 190.14% | 康托·菲茨杰拉德 | $3→$15 | 维护 | 超重 |
| 2022年05月13日 | -22.63% | 巴克莱 | $6→$4 | 维护 | 超重 |
| 04/01/2022 | - | SMBC日兴 | 评级下调 | 跑赢→中性 | |
| 03/31/2022 | - | 考恩公司 | 评级下调 | 跑赢→市场表现 | |
| 2021年11月16日 | - | 摩根大通 | 评级下调 | 中性→减持 | |
| 2021年11月05日 | 151.45% | 奥本海默 | $15→$13 | 维护 | 跑赢大盘 |
| 2021/08/18 | - | 摩根大通 | 评级下调 | 超重→中性 | |
| 03/02/2021 | 190.14% | 摩根大通 | $14→$15 | 假设 | →超重 |
| 01/07/2021 | 209.48% | 康托·菲茨杰拉德 | →$16 | 开始承保 | →超重 |
| 04/01/2020 | 441.59% | 奥本海默 | $29→$28 | 维护 | 跑赢大盘 |
| 2019/09/17 | 499.61% | 古根海姆 | →$31 | 开始承保 | →购买 |
| 2019年05月09日 | 306.19% | 巴克莱 | →$21 | 开始承保 | →超重 |
| 2019年08月30日 | 402.9% | 奥本海默 | →$26 | 开始承保 | →跑赢大盘 |
| 2018年12月17日 | 306.19% | 高盛 | $18→$21 | 升级 | 中性→购买 |
| 2018年11月26日 | 422.24% | 考恩公司 | →$27 | 开始承保 | →跑赢大盘 |
| 2018年11月26日 | 248.16% | 高盛 | →$18 | 开始承保 | →中性 |
| 2018年11月26日 | 383.56% | 韦德布什 | →$25 | 开始承保 | →跑赢大盘 |
| 2018年11月26日 | - | 摩根大通 | 开始承保 | →超重 |
What is the target price for Orchard Therapeutics (ORTX)?
Orchard Treeutics(ORTX)的目标价格是多少？
The latest price target for Orchard Therapeutics (NASDAQ: ORTX) was reported by Oppenheimer on August 9, 2023. The analyst firm set a price target for $34.00 expecting ORTX to rise to within 12 months (a possible 557.64% upside). 4 analyst firms have reported ratings in the last year.
奥本海默于2023年8月9日报道了果园治疗公司(纳斯达克：ORTX)的最新目标价。这家分析公司将目标价定为34美元，预计ORTX将在12个月内上涨至(可能上涨557.64%)。去年有4家分析公司公布了评级。
What is the most recent analyst rating for Orchard Therapeutics (ORTX)?
Orchard Treeutics(ORTX)的最新分析师评级是什么？
The latest analyst rating for Orchard Therapeutics (NASDAQ: ORTX) was provided by Oppenheimer, and Orchard Therapeutics reiterated their outperform rating.
奥本海默公司提供了对果园治疗公司(纳斯达克代码：ORTX)的最新分析师评级，果园治疗公司重申了他们的表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for Orchard Therapeutics (ORTX)?
Orchard Treeutics(ORTX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Orchard Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Orchard Therapeutics was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Orchard Treeutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Orchard Treeutics的上一次评级是在2023年8月9日提交的，所以你应该预计下一次评级将在2024年8月9日左右提供。
Is the Analyst Rating Orchard Therapeutics (ORTX) correct?
分析师对Orchard Treeutics(ORTX)的评级正确吗？
While ratings are subjective and will change, the latest Orchard Therapeutics (ORTX) rating was a reiterated with a price target of $0.00 to $34.00. The current price Orchard Therapeutics (ORTX) is trading at is $5.17, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的果园治疗公司(ORTX)评级被重申，目标价在0.00美元至34.00美元之间。果园治疗公司(ORTX)目前的交易价格为5.17美元，在分析师的预测范围内。